|
|
|
|
|
|
|
|
Quality by Design for Biotechnology Products—Part 2
|
|
|
| By
Taruna Arora
,
Roger Greene
,
Jennifer Mercer
,
Paul Tsang
,
Meg Casais
,
Stuart Feldman
,
Jutta Look
,
Tony Lubiniecki
,
Joseph Mezzatesta
,
Stefanie Pluschkell
,
Mark Rosolowsky
,
Anurag S. Rathore, PhD
,
Mark Schenerman
,
Tim Schofield
,
Samantha Sheridan
,
Paul Smock
,
Sally Anliker
,
Bernerd McGarvey
,
Bruce Meiklejohn
,
Jim Precup
|
|
|
|
Second in a three-part series that discusses the complexities of QbD implementation in biotech development.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Faking It
|
|
|
|
Drug counterfeiting has become a major problem for the FDA today; a variety of solutions is needed.
|
|
|
|
|
|
|
|
|
Speeding Up Slowly
|
|
|
| By
Laura Bush
|
|
|
|
Do we really have to choose between saving money and saving time?
|
|
|
|
|
|
|
|
|
Licensing of Expression Systems
|
|
|
| By
Eric S. Langer
|
|
|
|
Gaining a license can be a complex process, but a few key tips can help you avoid common pitfalls and patent infringements.
|
|
|
|
|
|